GlassScriptPhysician profile
David A Brubaker
NPI 1316919152
$897.41
in general payments reported to CMS, 2019-2025
14 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $52.78 · 2020: $150 · 2021: $257 · 2022: $235 · 2023: $203.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $203.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $202.51 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $338.04 | 2019-2023 | Rybelsus, Ozempic |
| Glaxosmithkline, LLC. | $155.78 | 2019-2023 | Trelegy Ellipta |
| Lilly USA, LLC | $90.97 | 2021-2023 | Mounjaro, Trulicity |
| Astrazeneca Pharmaceuticals LP | $59.23 | 2020-2023 | Farxiga |
| Merck Sharp & Dohme LLC | $45.71 | 2020-2021 | |
| Novartis Pharmaceuticals Corporation | $43.09 | 2022 | |
| Abbvie INC. | $40.94 | 2022-2023 | Mavyret |
| Pfizer INC. | $31.84 | 2019-2020 | |
| Amgen INC. | $21.85 | 2020 | |
| Bayer Healthcare Pharmaceuticals INC. | $16.82 | 2023 | |
| Astellas Pharma US INC | $16.49 | 2021 | |
| Kowa Pharmaceuticals America, INC. | $12.96 | 2021 | |
| Medtronic, INC. | $12.15 | 2021 | |
| Sanofi-Aventis U.S. LLC | $11.54 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Brubaker listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.